Small Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics

Bing-Jia Chen¹, Yan-Ling Wu²,¹, Yoshimasa Tanaka³ and Wen Zhang¹

1. Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, 18 Chaowang Road, Hangzhou, 310014, PR China.
2. Lab of Molecular Immunology, Virus Inspection Department, Zhejiang Provincial Center for Disease Control and Prevention, 630 Xinccheng Road, Hangzhou, 310051, China.
3. Center for Innovation in Immuno-regulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto, 606-8501, Japan.

Corresponding authors: Wen Zhang, Department of Biopharmaceutical Science, College of Pharmaceutical Sciences, Zhejiang University of Technology, 18 Chaowang Road, Hangzhou, 310014, China; Tel: +86-571-88871507; Fax: +86-571-88871507; e-mail: wzhang63@zjut.edu.cn. Yan-Ling Wu, Lab of Molecular Immunology, Virus Inspection Department, Zhejiang Provincial Center for Disease Control and Prevention, 630 Xinceng Road, Hangzhou, 310051, PR China; Tel: +86-571-87115282; Fax: +86-571-87115282; e-mail: ylwu@cdc.zj.cn; Both contributed equally to this work.

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License(http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2014.07.25; Accepted: 2014.08.25; Published: 2014.09.13

Abstract

The nuclear transcription factor c-Myc is a member of the Myc gene family with multiple functions and located on band q24.1 of chromosome 8. The c-Myc gene is activated by chromosomal translocation, rearrangement, and amplification. Its encoded protein transduces intracellular signals to the nucleus, resulting in the regulation of cell proliferation, differentiation, and apoptosis, and has the ability to transform cells and bind chromosomal DNA. c-Myc also plays a critical role in malignant transformation. The abnormal over-expression of c-Myc is frequently observed in some tumors, including carcinomas of the breast, colon, and cervix, as well as small-cell lung cancer, osteosarcomas, glioblastomas, and myeloid leukemias, therefore making it a possible target for anticancer therapy. In this minireview, we summarize unique characteristics of c-Myc and therapeutic strategies against cancer using small molecules targeting the oncogene, and discuss the prospects in the development of agents targeting c-Myc, in particular G-quadruplexes formed in c-Myc promoter and c-Myc/Max dimerization. Such information will be of importance for the research and development of c-Myc-targeted drugs.

Key words: c-Myc; small molecule; targeted therapy; tumor, G-quadruplex.

Introduction

As chronic non-infectious diseases, malignancy has become a serious threat to human health, and morbidity and mortality rates have been rising in recent years. At its most basal level, cancer is a genetic disease. It is challenging and interesting to develop effective therapy for cancer, because it comprises a heterogeneous group of diseases. Multiple factors are generally involved in its onset. As a result of synergistic or sequential damages of DNA, several proto-oncogenes such as c-Myc are activated and tumor suppressor genes are inactivated, leading to the alteration of DNA repair system and apoptosis regulation. Accumulation of the DNA damages may ultimately cause cell transformation.

Myc gene family comprises c-Myc, l-Myc, n-Myc, and so on. Based on the analysis so far, as many as 20% of human cancers can be associated with the overexpression of c-Myc. As a vital transcription regulator, c-Myc plays an essential role in the regulation of many physiological processes including cell cycle
control, apoptosis, protein synthesis, and cell adhesion [1]. Aberrant expression of c-Myc is likely to ascribable to direct gene alteration, which associates with tumorigenesis and sustained tumor growth [2-4]. Thus, the inhibition of c-Myc has promise as a therapeutic strategy for human cancer [5, 6]. Here we review structural and functional features of c-Myc and highlight to discuss possible small molecule modulators of c-Myc as promising anti-cancer therapeutics.

Structure of c-Myc

Some 20 years ago, c-Myc was discovered in human Burkitt’s lymphoma, as a cellular homologue of the viral oncogene v-Myc which was isolated from an avian retrovirus [7, 8]. On the basis of the study of v-Myc in chicken, the expression of human c-Myc was found to be altered in cancer. c-Myc is deregulated in a wide range of malignancies, such as mammary carcinoma, colon carcinoma, cervical carcinoma, myeloid leukaemia, melanoma osteosarcoma, glioblastoma, and small-cell lung carcinoma [8]. Human c-Myc (Fig. 1) is located on chromosome 8 q24.1 and consists of three exons and two introns [9].

![Figure 1: A schematic diagram of human c-Myc gene structure. The diagram shows the location of exons and promoters indicated by arrows. The region of a combination of transcription activators with DNA, the nuclease hypersensitivity element III1 (NHE III1), is located in the upstream of the P1 promoter.](http://www.ijbs.com)

The c-Myc transcription is regulated by multiple promoters. The nuclease hypersensitivity element III1 (NHE III1), also known as Pu27 with 27bp, controls 80-90% of the transcriptional activity of this gene [10-12]. This guanine (G)-rich element is located at -142~115 bp upstream of the P1 promoter and forms transcriptionally active double helix structure (Fig. 2). The G-rich strand can also form intramolecular G-quadruplex structure consisting of repeated sequences with three or four guanine residues to suppress c-Myc transcription in a silenced form [13]. Hence, the element is a potential target to down-regulate c-Myc overexpression in tumor cells.

As shown in Fig. 3, c-Myc protein is a 65 kDa nuclear phosphor-protein belonging to a basic helix-loop-helix leucine zipper (b/HLH/LZ) protein family [6, 13]. It is considered as a master regulatory factor of cell proliferation, metabolism, differentiation, and apoptosis. In humans, c-Myc dysregulation is one of the most common abnormalities found in cancer [14-19]. The c-Myc protein is composed of 439 amino acids (aa), which consists of an N-terminal transactivation domain (NTD), a C-terminal domain (CTD) and a central region. The N-terminal domain contains transcription activation domain (TAD) and three ~20 aa segments termed MYC box I, II, and III (MBI, MBII, and MBIII), which are essential for the biological functions of this protein [19, 20]. MBI and MBII are located at aa 45-63 and 129-143, respectively, and are responsible for the regulation of transcription and transformation. The C-terminal domain extends aa 360-437, which is essential for the association with b/HLH/LZ-interacting proteins such as the Myc-associated factor X (MAX). The heterodimerization of c-Myc with MAX plays a cardinal role in the proliferation, transformation, and apoptosis [21, 22].
Diverse Functions of c-Myc

The c-Myc oncoprotein has been shown to regulate the expression of about 15% of all human genes and to be involved in many physiological functions, such as cell cycle control, metabolism, protein biosynthesis, and microRNA regulation. In addition, c-Myc is involved in cell apoptosis and senescence, and DNA damage responses. c-Myc overexpression induces DNA damage response through the generation of reactive oxygen species and formation of aberrant DNA-replication intermediates. DNA damage response showed a dual role in tumor progression, including tumor suppression and tumor maintenance [1, 12, 23, 24]. The endogenous c-Myc thus has inherently contradictory features [24]. Herein, the current trends and perspectives in main c-Myc functions are summed up.

Regulation of cell cycle

The primary functions of c-Myc are to promote cell proliferation and to arrest cell differentiation [25-28]. The effect of c-Myc is mainly on the regulation of G1 phase transition in the cell cycle [33]. c-Myc has been shown to be involved in the activation and repression of cyclins D1 and D2, cyclin E, CDK4 (cyclin-dependent kinase 4) and cyclin B1 [22, 29-32]. By inducing the cyclin D-CDK2 (cyclin-dependent kinase 2) activity in the G1 phase of the cell cycle, c-Myc regulates the cell proliferation [33, 34]. The activation of CDK4 and cyclin D2 can lead to segregating p27Kip1 (cyclin-dependent kinase inhibitor 1B) from the cyclin D2-CDK4 complexes [35]. Under the conditions where KIP1 is dissociated with the cyclin E-CDK2 complexes, the complexes can be phosphorylated by the CAK (cyclin activating kinase) [22]. Other studies demonstrated that at the core promoter, c-Myc serves as a repressor of CDK inhibitors P15 and P21 through the interaction of c-Myc-Max heterodimer with transcription factors such as MIZ-1 [36-40]. But, the control of cellular proliferation and differentiation is a complex process requiring the coordination of growth factor induced signaling pathways, such as NF-kB (nuclear factor kB), HIFs (hypoxia inducible factors). NF-kB is an important DNA-binding transcription factors, which can activate of c-Myc and cyclin D1 to promote cell proliferation. Meanwhile, c-Myc also can repress NF-kB transactivation and induce sensitivity to TNF (tumor necrosis factor)-induced apoptosis [41]. And HIFs can alter cell-cycle progression through a putative transcription target such as cyclin D1 and indirect modulation of p21 and p27. The two α subunits of HIF-α, HIF-1α and HIF-2α respectively inhibits cell cycle progression and increases proliferation by promoting c-Myc and opposing c-Myc [42]. c-Myc is thus considered as a direct regulator of cell cycle regulation.

Ribosome biogenesis and protein synthesis

Besides as a cell cycle regulator, c-Myc has been also shown to coordinate protein synthesis. Many observations suggested that protein synthesis is regulated by c-Myc in multiple ways, in which the transcription of various RNA, iRNA, and ribosomes is controlled by the oncogene product [43]. In vivo, the rate of protein synthesis in c-Myc-overexpressed fibroblasts is three times higher than that in their parent cell lines [44]. The mechanisms underlying the regulation of protein synthesis by c-Myc are attributed to the regulation of transcription and ribosome biogenesis. Ribosome biogenesis has its own role in many coordination steps, such as synthesis and processing of ribosome RNA and ribosome proteins [43]. Until now, many genes of ribosomal proteins have been shown to be controlled by c-Myc [29, 45, 46]. Notably, c-Myc has a coordination action with nuclear RNA polymerases (RNA pol I and III) required in ribosome biogenesis and translation [33, 47-49]. Promotion of pol III transcription by c-Myc that directly binds TFIIB (transcription factor IIIB), a pol III-specific transcription factor, and pol III-transcribed tRNA and 5SrRNA genes plays an essential role in the regulation of cell cycle progression [33]. In addition, c-Myc also stimulates the transcription of rRNA (ribosomal
RNA), resulting in enhanced protein synthesis [47, 48, 50]. And recently research showed that c-Myc enhances protein synthesis during tumorigenesis not only through transcriptional control but also by activating mTOR (the mammalian target of rapamycin) dependent phosphorylation of 4EBP1 (eukaryotic translation initiation factor 4E binding protein 1). 4EBP1 is a master regulator of protein synthesis control and essential for cancer cells survival in c-Myc-dependent tumor development [51].

**Regulation of stem cell functions**

Many studies have proven that c-Myc plays a role in the regulation of stem cell function. With the cooperation of n-Myc, c-Myc inhibits the differentiation of stem cells, such as embryonic stem cells [52] and neural stem cells [52-54], and maintains their pluripotency and self-renewal. In addition, the functions of hematopoietic stem cells are regulated by c-Myc and n-Myc [55]. The ability of c-Myc to regulate the expression and function of stem cells is thus intricately linked to its oncogenic activity.

**Cell apoptosis**

c-Myc is not only an inducer of cell proliferation, but also has the ability to regulate cell apoptosis via various signaling pathways [56, 57]. The mechanism by which c-Myc induces apoptosis has not been fully elucidated. Two major pathways have been, however, proposed [57]. One signaling pathway is that c-Myc induces expression of ARF, a tumor suppression protein which is transcribed from an alternate reading frame of the INK4a/ARF locus. When P19Arf binds Mdm2 (mouse double minute 2), P53 (tumor protein p53) is activated and promotes apoptosis via activation of proapoptotic genes and cell cycle mediators [56, 58-60]. The other one is that c-Myc regulates apoptosis by repressing the expression of anti-apoptotic proteins, such as Bcl-2 (B-cell lymphoma 2), which blocks mitochondrial outer membrane permeabilization and inhibits cytochrome c release from mitochondria [61-63].

**miRNA expression**

Recently, evidence has been accumulating that c-Myc also regulates the expression of miRNAs, which are a set of small, non-protein-coding RNAs and regulate gene expression at the post-transcriptional level [64-69]. Little is, however, known about how c-Myc regulates the expression of miRNAs [70]. So far, many factors, such as SMAD (drosophila mothers against decapentaplegic) [71, 72], P53 (tumor protein p53) [73], ATM (ataxia telangiectasia mutated) [74], MutLα (MLH1-PMS2 heterodimer) [75], and BRCA1 (breast cancer 1) [76], have been shown to interact with microprocessor complexes and modulate the expression of miRNAs. Through enhancing the expression of Drosha (Fig. 4), a c-Myc target gene, c-Myc indirectly promotes the processing of miRNAs [70]. Proper manipulation of the c-Myc-miRNA may lead to a novel therapy for malignancies.

**c-Myc as a Therapeutic Target**

c-Myc is expressed in most human hepatic cells, and is closely involved in cell cycle, differentiation, protein synthesis, and apoptosis in normal as well as neoplastic cells. Hence, c-Myc is one of the most important targets in the development of cancer treatment [77]. Here, we particularly review current progress in main small-molecule ligands that can induce and stabilize G-quadruplexes formed in c-Myc promoter sequences and inhibit c-Myc/Max dimerization, leading to the inhibition of cancer cell proliferation. Whereas until now people have not succeeded in developing any drug targeting c-Myc, which can be utilized in clinics [78]. Therefore, it is worth challenging to create novel small molecule compounds that can specifically inhibit the functions of c-Myc and be used to alleviate the suffering of cancer patients.

**Small-molecule ligands targeting the c-Myc promoter G-quadruplexes**

Advances in the development of anti-tumor drugs targeting the c-Myc promoter G-quadruplexes. G-quadruplexes have been shown to be a promising target for anti-cancer therapy, based on their functions in regulating c-Myc transcription and suppressing tumorigenicity. As shown in Fig. 1, nuclease hypersensitive element (NHE) III1, a G-rich sequence of c-Myc promoter, has two different forms, transcriptionally active and silenced forms; When the G-rich sequence exists in the form of double helix, RNA polymerases in cooperation with various other
factors can transcribe c-Myc gene, and in contrast, the silenced form, containing G-quadruplexes, prevents the various transcription factors from interacting with the element, leading to a down-regulation of c-Myc transcription [77]. Under physiological conditions, however, very few G-quadruplexes exist in the c-Myc promoter region [78, 80]. Since G-quadruplexes play important roles in the repression of c-Myc, small-molecule ligands that can specifically induce the formation of and stabilize the G-quadruplex in vivo may be developed as promising anti-cancer drugs [77, 81]. Until now, only one small-molecule compound CX-3543 (Quarfloxin) (Fig. 5) has entered phase II clinical trials for neuro-endocrine carcinomas (NCT00780663), which targets selectively the Myc G-quadruplexes by interacting with the site between planes in the π-π patterns in vitro based on the determination through NMR (nuclear magnetic resonance), PCR-stop, and MSi (molecular simulation studies). Although CX-3543 was selected as a binder of Myc G-quadruplex, it was preferred to disrupt nucleolin/G-quadruplex complexes in the nucleolus to interact with the biosynthesis of ribosomal RNA in cancer cells and induce apoptosis in cancer cells [82, 83].

**Perylene derivatives:** Perylene compounds have been reported to strongly interact with G-quadruplexes [86]. As shown in Fig. 5, a representative of these derivatives, N,N'-bis(2-(1-piperidino)ethyl)-3,4,9,10-perylenetetracarboxylic acid diimide (PIPER), induces the formation of G-quadruplex from duplex of the c-Myc Pu27-mer sequence through end stacking interaction with G-tetrads [84, 85]. In addition, Pivot and colleagues [86] synthesized a number of perylene derivatives [Fig. 5] with linear or cyclic amines in the side chains. The binding affinity and selectivity of perylenes to G-quadruplexes depends on the structure of the side chains. To develop novel compounds with higher affinity on the basis of the structure-affinity relationship, further synthetic studies should be carried out.

![Figure 5: Some small-molecules that bind c-Myc promoter G-quadruplexes.](http://www.ijbs.com)
Cationic porphyrins: As a G-quadruplex ligand and a representative of cationic porphyrins, TMPyP4 (Fig. 5) [87] is of special concern. Based on microcalorimetric (ITC, isothermal titration calorimetry, and DSC, differential scanning calorimetry), spectrometric (UV-vis and CD, circular dichroism), and molecular simulation (MSi) studies, TMPyP4 has been proven to down-regulate the expression level of c-Myc through combining with G-quadruplexes of Pu27 [77]. Upon incubation with TMPyP4, G-quadruplex structure undergoes transformation from a parallel type to hybrid with parallel and anti-parallel types, with the ratio of 1:4 at a saturated condition [89]. In addition, TMPyP4 can also interact with some G-rich sequences and stabilize i-motif structures that promote the formation of G-quadruplexes [89, 90]. TMPyP4 is thus a promising agent as a lead compound for a novel anti-cancer therapy targeting G-quadruplexes [91]. Owing to the poor selectivity of TMPyP4, however, TMPyP4 itself cannot be used as a therapeutic. Hurley and colleagues designed and synthesized a novel derivative, Se2SAP (Fig. 5), with a porphyrin ring core [92]. Compared to TMPyP4, Se2SAP has higher affinity to G-quadruplexes of c-Myc in comparison with double-stranded DNA and other G-quadruplexes. Se2SAP can convert the parallel G-quadruplexes of the c-Myc Pu27 into a hybrid G-quadruplex with parallel and anti-parallel structures. Based on these studies, Se2SAP is hopefully to become the first compound that can identify different conformations of G-quadruplexes because of its lower photosensitivity and less toxicity [12].

Quindolines: Gu and colleagues designed and synthesized a series of quindolines [93], which can induce the sequence of the c-Myc promoter Pu27 to form G-quadruplex structure and stabilize it. By repressing the transcription of c-Myc in HepG2 cells, these compounds inhibit the growth of tumour cells. These derivatives have higher affinity to G-quadruplexes than to other DNA structures. The side chains are shown to determine the binding affinity and selectivity. Quindoline derivatives with tertiary amine in the side chains (Fig. 5) such as SYUIQ-05, are more likely to interact with c-Myc G-quadruplexes than telomere G-quadruplexes [94]. The n-n docking is considered to be the primary determinant in the interaction.

Hoechst 33258: It has been demonstrated that the synthetic dye Hoechst 33258 (Fig. 5) can convert Pu27 to G-quadruplexes [84]. The compound interacts with AAGT loop of G-quadruplexes of Pu27.

Alkaloids: From a long-term perspective, natural products have been a prodigious source of compounds with therapeutic activity and low toxicity in the development of tumor-selective therapies [95, 96], of which telomestatin has been shown to be one of the most potent G-quadruplex ligands [97]. Thus, natural products are a pre-existing small molecule library for screening new anti-cancer targeted drugs [98]. Natural alkaloids, a series of compounds of traditional Chinese medicine (TCM), can interact with DNA to form complexes [99]. Ji and coworkers examined the interaction of a number of natural alkaloids [Fig. 6] with G-quadruplexes formed by c-Myc Pu27.

**Figure 6: Structures of some natural alkaloids.** (A) Structures of four natural alkaloids with similar structures: sanguinarine (San), palmatine (Pal), berberine (Beb), tetrahydropalmatine (Tep) and several Beb derivatives; (B) structures of 7 alkaloids with a backbone of bis-benztetrahydroisoquinoline.
Among them, sanguinarine (San), beberine (Beb), palmatine (Pai), and tetrahydropalmatine (Tep) (Fig. 6) can induce the formation of and stabilize G-quadruplexes. Except for Tep, the examined compounds contain unsaturated ring C and positively charged centers N+ that enhance the interaction with G-quadruplexes through expanding the conjugate system. Especially, the study by Ji et al showed that San had the highest ability to stabilize the structure of G-quadruplexes and inhibit cell growth and that the interaction is mediated by external stacking or intercalating [100]. Other alkaloids with similar structures in Fig. 6 also have comparable ability to stabilize G-quadruplexes. A 9-substituted derivative of Beb with an alkyl side chain carried with a terminal amino group synthesized by Huang and colleagues had higher binding affinity to G-quadruplexes than the original compound [101, 102]. Furthermore, quinolino-benzo dihydroisoquindolium (QBDI) was synthesized by modifying the 9-substituted Beb. All of the Beb and QBDI derivatives can interact with the c-Myc G-quadruplex with high selectivity [103].

**Metal complexes:** Varieties of metal-containing small molecules have been demonstrated to interact with G-quadruplexes [104, 105]. As clinical drugs used in chemotherapy, cisplatin and its analogs have conceivable adverse effects, such as renal toxicity and treatment-induced resistance. It is thus indispensable to design novel, well-tolerated metal complexes for anti-cancer therapies [106, 107]. In recent years, a number of metal complexes have been reported to interact with G-quadruplexes and stabilize them [108]. Platinum (II) complexes (Pt (II)) can serve as stabilizers of G-quadruplexes [108, 109], since they can strongly interact with G-quadruplexes. It is worthy of note that these studied complexes show only weak binding affinity to duplex DNA. Wang and coworkers designed and synthesized a Pt (II) (Fig. 5) which improved the selectivity of Pt (II) binding to G-quadruplexes over duplex DNA. Based on the experimental data, [Pt(Dip)2]PF6 shows greater binding affinity to c-Myc parallel G-quadruplexes than to duplex DNA [110]. In addition, many other complexes containing Zn+, Ni2+, Cu+, Mn2+, Ru2+, V4+ and so on, have been evaluated for binding to G-quadruplexes [109]. As well as traditional organic heteroaromatic compounds, various metal complexes have emerged as an increasing important type of compounds in search of novel G-quadruplex binders with strong and selective affinity and potential anticancer activity.

Many small-molecule ligands discussed above, such as quindolines [86], cationic porphyrins [93], platinum complexes [111], can repress the transcription of c-Myc by inducing the formation of c-Myc G-quadruplexes and stabilizing them. Most G-quadruplex ligands containing aromatic planes can stack on the end of G-quadruplexes by a n-n interaction [105]. Only a few ligands, such as Hoechst 33258, have been reported to bind to G-quadruplex grooves and loops [112], which have high selectivity in interacting with different topologies of G-quadruplexes [113]. Also, Chen et al. predicted that 3', 3'-diethylloxadicarbocyanine (DODC) can bind to G-quadruplex grooves [114], and it was proved in their subsequent studies [115, 116].

**Carbamide and its analogues:** Different from most above-discussed compounds with a few large conjugated aromatic planes, Carbamide 1 (Fig. 7) identified by Ma and colleagues, a natural product, can act as a stabilizer of c-Myc G-quadruplexes through binding with G-quadruplex grooves. NMR and MSi revealed that carbamide 1 could control c-Myc gene transcription. The interaction of carbamide analogues 1-5 with G-quadruplexes was examined and it was demonstrated that carbamide 1 with variable diphenyl ether units had the highest activity in binding to G-quadruplexes [117].

**Other ligands:** In process of exploring small-molecule ligands, the effect of telomerase inhibitors (Fig. 7) on the stabilization of c-Myc promoter G-quadruplexes was examined. It was demonstrated that a variety of telomerase inhibitors effectively stabilized G-quadruplexes of the c-Myc promoter, and that the affinity of compounds TMPyP4 and 12459 to the c-Myc promoter G-quadruplexes was two-fold higher than that to the G-quadruplexes of telomere [118].

**Binding modes of ligands to the c-Myc gene promoter G-quadruplexes.** Through targeting G-quadruplexes, small-molecule ligands play pivotal roles in the regulation of c-Myc gene transcription. There are three basic binding modes of the ligands with G-quadruplexes (Fig. 8) [104, 119]: (1) external stacking: ligands with a π-delocalized system stack on the end of G-quadruplexes via n-n stacking; (2) intercalating: ligands insert into the interspace of two G-tetrad planes; and (3) groove or loop nonspecific binding: ligands bind to the grooves or loops of the G-quadruplexes. In the absence of the interaction between internal cation and electrical body of G-quadruplexes, the binding of the molecules at the end of the G-tetrad is easier and more stable than intercalating in lower energy [120]. Therefore, the small-molecule ligands are prone to interact with the c-Myc G-quadruplexes in an external stacking-manner.
Small molecule modulators of c-Myc/Max dimerization

c-Myc, a DNA-binding transcriptional regulator, functions through heterodimerization with another basic-helix-loop-helix leucine zipper (BHLH-LZ) transcription factor, MAX [1, 121]. The c-Myc/Max complex recognizes DNA response elements, such as a specific sequence E-box or other target genes to activate c-Myc-mediated transcription [121]. The interaction and heterodimerization between c-Myc and Max are required in the regulation of all known functions of c-Myc, including regulation of cell proliferation, apoptosis, and target gene transcription [1, 2, 121]. There are two ways to modulate the c-Myc/Max functions (Fig. 9): to inhibit c-Myc/Max dimerization and to disrupt their DNA recognition [122]. Some small molecules can downregulate c-Myc functions through not only inducing the formation of and stabilizing G-quadruplexes, but also targeting c-Myc in a different manner, such as inhibiting c-Myc/Max dimerization or their binding to E-box motifs, and disturbing the interaction of c-Myc with other factors. Thus, small molecules that can inhibit the c-Myc/Max dimerization or binding to E-box motifs may serve as potential tumor therapeutics.

Small-molecule inhibitors of c-Myc/Max dimerization. As well as small nonpeptide molecules, which interfere with the dimerization of c-Myc/Max, a number of small-molecule inhibitors of c-Myc/Max dimerization have been discovered in the last decade [123-125]. However, the design of c-Myc inhibitors is still challenging due to a lack of obvious binding sites in the c-Myc/Max interface [1]. Most of the inhibitors thus far obtained were screened from chemical libraries [126]. The peptide mimetic compound IIA6B17 (Fig. 10) was identified as the first small-molecule inhibitor of c-Myc/Max by Vogt and colleagues [127]. Recently, using a reporter system, it was shown that IIA6B17 inhibited c-Myc transcription and interfered with c-Myc/Max dimerization [128]. These high throughput screening studies pave the way of the discovery of new inhibitors of c-Myc/Max heterodi-
mer or c-Myc/Max/DNA complex formation [123-125, 129-135]. Likewise, a compound NY2267 (Fig. 10) and its structurally related derivatives were shown to strongly inhibit c-Myc/Max binding to DNA by groups of Janda and Vogt [124]. NY2267, however, indiscriminately inhibits transcription mediated by c-Jun and c-Myc, since they are similar in their dimer structures [123]. Because all of these small molecules so far identified require high concentrations for the inhibition of c-Myc/Max/DNA complex, it has been difficult to develop c-Myc-targeted anti-cancer therapeutics [124]. Prochwnik and co-workers designed and reported seven small-molecule inhibitors of c-Myc/Max including 10058-F4 and 10074-G5 (Fig. 10) [136]. They first synthesized derivatives based on the structure of 10058-F4 (IC50 = 49 μM on HL60 cells), of which 28RH-NCN-1 exhibited more potent activity in inhibiting the binding of c-Myc/Max to E-box motifs than the parent compound 10058-F4 [124, 129]. On the basis of the structure-activity relationship of the derivatives, pharmacophore analysis demonstrated that 31122-64-2 and 307545-04-6 inhibited the c-Myc/Max/DNA complex formation through inhibiting DNA binding of c-Myc [137]. Then, it was reported that JY-3-094 (Fig. 10), an analog of 10074-G5, could interfere with the association between recombinant c-Myc and Max five-times more efficiently than the parent compound, whereas the analog has poor cell permeability. Thus, a p-carboxylic acid moiety of the analog was esterified to optimize the cellular uptake and retention. The prodrug compound JY-3-094 [138] and its derivatives would warrant further optimization of small-molecule c-Myc/Max inhibitors.

![Figure 9: Transcriptional regulation by c-Myc and inhibition of c-Myc functions by small molecules.](image)

**Figure 9**: Transcriptional regulation by c-Myc and inhibition of c-Myc functions by small molecules. Left: The binding of c-Myc/Max dimers to E-box elements (CACGTG) activates the transcription of c-Myc-regulated genes. Right: The inhibition of the c-Myc/Max dimerization or c-Myc/Max DNA binding represses the transcription of genes regulated by c-Myc/Max.

![Figure 10: Small molecules capable of inhibiting transcriptional regulation by c-Myc.](image)

**Figure 10**: Small molecules capable of inhibiting transcriptional regulation by c-Myc. (A) Small-molecule inhibitors of c-Myc/Max dimerization; (B) small-molecule inhibitors of c-Myc/Max/DNA complex formation.
Berg and co-workers designed and synthesized two other small molecules, the pyrazolo [1,5-a] pyrimidine Mycro 1 and its derivative Mycro 2 (Fig. 10), which inhibit the interaction between c-Myc and Max [125]. Based on the structure of the compounds, pyrazolo [1,5-a] pyrimidine Mycro 3 was also synthesized, which had high selectivity and inhibited c-Myc/Max dimerization and conjugation with DNA [131]. Because Mycro 3 is potent and selective for c-Myc in whole assays, with weak inhibitory activity against AP-1, this compound has a superior specificity profile to its predecessors. Mycros are the first inhibitors of c-Myc/Max dimerization, and also inhibit c-Myc/Max/DNA binding, in which the compounds preferentially interact with c-Myc/Max over other related dimeric transcription factors [125]. The mechanisms underlying the inhibition of c-Myc/Max heterodimerization by these small molecules have been unclear until recently. Small-molecule inhibitors were shown to bind one of the three discrete binding sites on the c-Myc bHLH-Zip domain [132, 139]. Using a fluorescence polarization (FP) assay, Metallo and colleagues demonstrated that 10058-F4 and 10074-G5 interacted with c-Myc402-412 and c-Myc363-381, respectively. These two compounds could bind to their specific amino acid residues simultaneously and independently. Besides these two distinct binding sites, a third one in the c-Myc bHLH-Zip domain was identified, with which the compound 10074-A4 could interact. It is worthy of note that the three binding sites are functionally independent and mutually exclusive [132]. When the molecules bind to their distinct binding sites of c-Myc, the oncoprotein may form a more rigid and defined conformation than c-Myc/Max heterodimer, resulting in the dissociation between c-Myc and Max [139].

**Small-molecule inhibitors of c-Myc/Max DNA binding.** Inhibitors of c-Myc/Max/DNA complexes block c-Myc induced transcription. It is worth noting that two compounds, MYRA-A and NSC308848 (Fig. 10), have high selectivity in targeting the DNA binding domain of c-Myc/Max. The inhibitors thus can suppress the expression of gene products regulated by c-Myc and the induction of apoptosis [136, 140].

**Future Prospects**

Because of its oncogenic properties in neoplastic cells, c-Myc has become an interesting and feasible target for novel therapies of a variety of human malignancies related to c-Myc. It has been shown that several small molecules target the transcription of c-Myc gene directly or the c-Myc downstream pathway. Especially, G-rich region of c-Myc promoter has become a promising target. Many reports demonstrate that low-molecular weight compounds have a potential to be developed into therapeutic drugs in individualized cancer therapy. Even with the advances in the field of drug design and in the mechanisms underlying the c-Myc overexpression in tumor cells, it is still difficult to obtain highly specific and active anti-cancer drugs. Through the identification of various small molecular compounds that interfere with c-Myc, it may be possible to develop novel and effective therapeutic agents to treat cancer.

**Abbreviations**

CNPB: cellular nucleic acid binding protein; hnRNP: heterogeneous nuclear ribonucleoprotein; TBP: TATA-box-binding protein; RNA Pol II: RNA polymerase II; CDK4: cyclin-dependent kinase4; CDK2: cyclin-dependent kinase 2; p27Kip1: cyclin-dependent kinase inhibitor 1B; CAK: cyclin activating kinase; NF-xB: nuclear factor kB; HIFs: hypoxia inducible factors; TNF: tumor necrosis factor; TFIIB: transcription factor IIIB; rRNA: ribosomal RNA; mTOR: the mammalian target of rapamycin; 4EBP1: eukaryotic translation initiation factor 4E binding protein 1; Mdm2: mouse double minute 2; P53: tumor protein p53; Bcl-2: B-cell lymphoma 2; SMAD: drosophila mothers against decapentaplegic; ATM: ataxia telangiectasia mutated; MutLα: MLH1-PM2 heterodimer; BRCA1: breast cancer 1; NMR: nuclear magnetic resonance; MSi: molecular simulation; ITC: iso-thermal titration calorimetry; DSC: differential scanning calorimetry; CD: circular dichroism.

**Acknowledgements**

We gratefully acknowledge the financial support from Zhejiang Provincial Natural Science Foundation of China (LY12B02019), the Qianjiang Talents Program of Zhejiang Province (2009R10002) and the Program for Zhejiang Leading Team of Science and Technology Innovation (2011R50021).

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. Dang C V. MYC on the Path to Cancer. Cell. 2012; 149(1): 22-35.
2. Fernandez PC, Frank S R, Wang L, et al. Genomic targets of the human c-Myc protein. Genes & development. 2003; 17(9): 1115-1129.
3. Li Z, Van Calcar S, Qu C, et al. A global transcriptional regulatory role for c-Myc in Burkitt’s lymphoma cell. PNAS. 2005; 100(14): 8164-8169.
4. Lin CY, Loven J, Rahb PB, et al. Transcriptional amplification in cancer cells with elevated c-Myc. Cell. 2012; 151(1): 56-67.
5. Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer cell. 2012; 21(4): 506-523.
6. Berg T. Small-molecule modulators of c-Myc/Max and Max/Max interaction. Curr Top Microbio Immunol. 2011; 348: 139-149.
7. Lin CP, Liu CR, Lee CN, et al. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol. 2010; 2(11): 16-20.
8. Zhang W, Kater AP, Widhopf GF, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. PNAS. 2010; 107(44): 18956-18960.
9. Watt R, Nishikura K, Sorrentino J, et al. The structure and nucleotide sequence of the 5’end of the human c-Myc oncogene. PNAS. 1983; 80(20): 6307-6311.

10. Islam MA, Thomas SD, Murty VV, et al. c-Myc quadruplex-forming sequence PuPu induces transactivation damage in both telomeric and non-telomeric regions of DNA. J Biol Chem. 2014; [nc13]:5057073.

11. Simonsson T, Pribylova M, Vorlickova M. A Nuclease Hypersensitive Element in the human c-myc promoter adopts several distinct 1-tetraplex structures. Biochim Biophys Acta. 2002; 1578(1): 156-166.

12. Shenassy J, Bashamy S, Gokhale V, et al. Design and synthesis of an expanded porphyrin that has selectivity for the c-Myc-G quadruplex structure. J Am Chem Soc. 2005; 127(9): 2944-2959.

13. Cashman DJ, Bussaglia R, Freyer MW, et al. Molecular modeling and bio-physiological analysis of the c-MYC NE-ILL1 silencer element. J Mol Biol. 2008; 41(2): 93-101.

14. Soucek L, Evan G. Myc-Is this the oncogene from Hell? Cancer Cell. 2002; 1(5): 462-408.

15. Vafa O, Wade M, Kern S, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002; 9(5): 1031-1044.

16. Zhang Q, Spears E, Boone DN, et al. Domain-specific c-Myc ubiquitination controls c-Myc transcriptional and apoptotic activity. PNAS. 2013; 110(3): 978-983.

17. Song G, Li Y, Zhang Z, et al. c-myc but not Hif-1α-dependent downregulation of VEGF influences the proliferation and differentiation of HL-60 cells induced by ATRA. Oncol Rep. 2009; 23(6): 2563-2568.

18. Alibhain A, Johnson J, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107: 163-224.

19. Delmore JE, Isa GCA, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-MYC. Cell. 2011; 146(6): 904-917.

20. Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene. 1999; 18(19): 2942-2954.

21. Ponzelli R, Katz S, Barsyte-Lovejoy D, et al. Cancer therapies: targeting the right side of Myc. Nat Rev. 2005; 41(16): 2485-2491.

22. Pellenq R, Khan M. The many faces of c-Myc. Arch Biochem Biophys. 2003; 416(2): 129-136.

23. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1): 68-79.

24. Carvitt P, McLean C, Sheppard A, et al. LIF/STAT3 controls expression of the c-Myc gene. J Biol Chem. 2003; 278(2): 12976-12983.

25. Alibhain A, Johnson J, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107: 163-224.

26. Fernandez PC, Frank SR, Wang L, et al. Genomic reprogramming by Myc and c-Myc in the regulation of p21CIP1/WAF1 and p15INK4b controls c-Myc and c-Myc induced DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002; 9(5): 1031-1044.

27. Zhang Q, Spears E, Boone DN, et al. Domain-specific c-Myc ubiquitination controls c-Myc transcriptional and apoptotic activity. PNAS. 2013; 110(3): 978-983.

28. Song G, Li Y, Zhang Z, et al. c-Myc but not HIF-1α-dependent downregulation of VEGF influences the proliferation and differentiation of HL-60 cells induced by ATRA. Oncol Rep. 2009; 23(6): 2563-2568.

29. Alibhain A, Johnson J, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107: 163-224.

30. Delmore JE, Isa GCA, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-MYC. Cell. 2011; 146(6): 904-917.

31. Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene. 1999; 18(19): 2942-2954.

32. Ponzelli R, Katz S, Barsyte-Lovejoy D, et al. Cancer therapies: targeting the right side of Myc. Nat Rev. 2005; 41(16): 2485-2491.

33. Pellenq R, Khan M. The many faces of c-Myc. Arch Biochem Biophys. 2003; 416(2): 129-136.

34. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1): 68-79.

35. Carvitt P, McLean C, Sheppard A, et al. LIF/STAT3 controls expression of the c-Myc gene. J Biol Chem. 2003; 278(2): 12976-12983.

36. Alibhain A, Johnson J, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107: 163-224.

37. Fernandez PC, Frank SR, Wang L, et al. Genomic reprogramming by Myc and c-Myc in the regulation of p21CIP1/WAF1 and p15INK4b controls c-Myc and c-Myc induced DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002; 9(5): 1031-1044.

38. Zhang Q, Spears E, Boone DN, et al. Domain-specific c-Myc ubiquitination controls c-Myc transcriptional and apoptotic activity. PNAS. 2013; 110(3): 978-983.

39. Song G, Li Y, Zhang Z, et al. c-Myc but not HIF-1α-dependent downregulation of VEGF influences the proliferation and differentiation of HL-60 cells induced by ATRA. Oncol Rep. 2009; 23(6): 2563-2568.

40. Alibhain A, Johnson J, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107: 163-224.

41. Delmore JE, Isa GCA, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-MYC. Cell. 2011; 146(6): 904-917.

42. Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene. 1999; 18(19): 2942-2954.

43. Ponzelli R, Katz S, Barsyte-Lovejoy D, et al. Cancer therapies: targeting the right side of Myc. Nat Rev. 2005; 41(16): 2485-2491.

44. Pellenq R, Khan M. The many faces of c-Myc. Arch Biochem Biophys. 2003; 416(2): 129-136.

45. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1): 68-79.

46. Carvitt P, McLean C, Sheppard A, et al. LIF/STAT3 controls expression of the c-Myc gene. J Biol Chem. 2003; 278(2): 12976-12983.

47. Alibhain A, Johnson J, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107: 163-224.

48. Fernandez PC, Frank SR, Wang L, et al. Genomic reprogramming by Myc and c-Myc in the regulation of p21CIP1/WAF1 and p15INK4b controls c-Myc and c-Myc induced DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002; 9(5): 1031-1044.
87. Halder K, Mathur V, Chugh D, et al. Quadruplex-duplex competition in the nuclease hypersensitive element of human c-myc promoter: Cto T mutation in C-rich strand enhances duplex association. Biochim Biophys Res Commun. 2004; 327:49-56.

88. Li W, Miyoshi D, Nakano S, et al. Structural competition involving G-Quadruplex DNA and its complement. Biochemistry. 2003; 42:11736-11744.

89. Ristaino A, Fox KR. Stability of intramolecular DNA quadruplexes: comparison with DNA double helix. Biochemistry. 2003; 42(21): 6507-6513.

90. Franceschini M. G-Quadruplex DNA structures and organic chemistry: more than one connection. Eur J Org Chem. 2009; 2009(14): 2225-2238.

91. Steele NL, Plumb J A, Vidal L, et al. A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008; 14(3): 804-810.

92. Brooks TA, Hurley LH. Targeting MYC expression through G-Quadruplexes. Genes & cancer. 2010; 1(6): 641-649.

93. Kerwin SM, Chen G, Kern JT, et al. Perylene diimide G-Quadruplex DNA binding selectivity is mediated by ligand aggregation bioorg. Med Chem Lett. 2012; 2(3): 447-450.

94. Li Q, Xiang JF, Zhang H, et al. Searching drug-like anti-cancer compound (s) against telomeric quadruplexes. Angew Chem Int Ed. 2018; 18(14): 1973-1983.

95. Pitveta C, Lucatello L, Lrapelo AP, et al. Perylene side chains modulate G-Quadruplex conformation in biologically relevant DNA sequences. Bioorg Med Chem. 2008; 16(20): 9331-9339.

96. Sun D, Guo K, Rusche JJ, et al. Facilitation of a structural transition in the parallel G-Quadruplex/pyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-Quadruplex-interactive agents. Nucleic Acids Res. 2005; 33(18): 6070-6080.

97. Kato GJ, Barrett J, Villa-Garcia M, et al. An amino-terminal c-myc domain required for parallel DNA and transcription activates transcription. Mol Cell Biol. 1990; 10(11): 5914-5920.

98. Seeversamy J, Rezler EM, Powell TJ, et al. The dynamic character of the G-Quadruplex element in the c-MYC promoter and modification by TMPyP4. J Biol Chem. 2010; 285(26): 20377-20385.

99. Gonzalez V, Hurley L H. The c-MYC NHE III function: regulation and function. Annu Rev Pharmacol Toxicol. 2010; 50: 111-129.

100. Andrew Ej, Merchan S, Lawless C, et al. Pentose phosphate pathway function affects tolerance to the G-Quadruplex binder TMPyP4. Plosh one. 2013; 8(6): e62642.

101. Verdun RE, Karheder J. Replication and protection of telomeres. Nature. 2007; 447(7147): 924-931.

102. Ou TM, Lu Y, Zhang C, et al. Stabilization of G-Quadruplexes DNA and down-regulation of oncogene c-myc by quindoline derivatives. J Med Chem. 2010; 53(7): 1465-1474.

103. Ou TM, Jin L, Lu YJ, et al. Inhibition of cell proliferation by quindoline derivative (SYU263) through its preferential interaction with telomeric DNA and c-myc promoter G-Quadruplexes. J Med Chem. 2011; 54(16): 5671-5679.

104. Efferth T, Fu Y, Zou H, et al. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr Med Chem. 2007; 14(19): 2041-2052.

105. Lee HM, Chon DS, Yang F, et al. Identification of natural product Forsonic B as a stabilizing ligand of c-myc G-Quadruplex DNA by high-throughput vitrual screening. Chem Commun. 2010; 46(26): 4801-4802.

106. Shi C, Yu K, Wei C, Matsuo K, et al. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus J. Am Chem Soc. 2001; 123(6): 1262-1263.

107. Liu Y, Zheng B, Xu X, et al. Probing the binding affinity of small-molecule natural products to the G-quadruplexes in c-myc oncogene by electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2010; 24(20): 3072-3075.

108. Maiti M, Kumar GS. Proteobacterial alkaloids: physicochemical and nucleic acid binding properties. Top Heterocycl Chem. 2007; 10: 155-209.

109. Berg T. Inhibition of transcription factors with small organic molecules. Curr Opin Chem Biol. 2008; 12(4): 464-471.

110. Wang H, Hammoudeh DI, Follis AV, et al. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther. 2007; 6(9): 2399-2408.

111. Kiesling A, Sperl B, Hollis A, et al. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol. 2006; 13(7): 745-751.

112. Yap JL, Chauhan J, Jung KY, et al. Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein-protein and protein-DNA interactions. Med Chem Comm. 2012; 3(5): 541-551.

113. Berg T, Cohen SB, Darnaraj J, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. PNAS. 2002; 99(9): 8303-8308.

114. Lu X, Vogt PK, Boger DL, et al. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep. 2008; 19(3): 6305-6310.

115. Yin X, Gao C, Lazo JS, et al. Low molecular weight inhibitors of Myc/Max interaction and function. Oncogene. 2003; 22(40): 6151-6159.

116. Xu Y, Shi J, Yamamoto N, et al. A credit-card library approach for disrupting protein-protein interactions. Biochem Med. 2006; 16(2): 260-263.

117. Kiesling A, Wiesinger A, Sperl B, et al. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a] pyrimidine. ChemMedChem. 2007; 2(5): 627-630.

118. Hammoudeh DI, Follis AV, Prochownik EV, et al. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc. 2009; 131(21): 7390-7401.

119. Shi J, Stover JS, Whitby LR, et al. Small molecule inhibitors of Myc/Max induced cell transformation. Bioorg Med Chem Lett. 2009; 19(21): 6038-6041.

120. Follis AV, Hammoudeh DI, Daab AT, et al. Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg Med Chem Lett. 2009; 19(21): 6038-6041.

121. Guo J, Farise RA, Joseph E, et al. Efficacy, pharmacokinetics, tissue distribution, and metabolism of the Myc-Max disruptor, 10088-F4 [Z, E]-5-[4-ethylbenzydzide]-2-thiophenoxazolidin-4-one, in mice. Cancer Chemother Pharmac. 2009; 64(4): 615-625.

122. Mo H, Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. PNAS. 2006; 103(16): 6344-6349.

123. Mustata G, Follis AV, Hammoudeh DI, et al. Discovery of novel myc-max heterodimer inhibitors with a three-dimensional pharmacophore model. J Med Chem. 2009; 52(5): 1247-1250.

124. Wang H, Chauhan J, Hu A, et al. Disruption of Myc-Max Heterodimerization with Improved Cell-Perforating Analogues of the Small Molecule 10074-C5. Oncotarget. 2013; 4(6): 936-952.

125. Follis AV, Hammoudeh DI, Wang H, et al. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol. 2008; 15(11): 1149-1155.
Myc overexpression enhances apoptosis induced by small molecules. Cell Cycle. 2006; 5(19): 2191-2194.

Author biography

Bing-Jia Chen is a postgraduate majoring in pharmacy. She obtained the Bachelor’s Degree in Bio-pharmaceutical Engineering in 2012 from Zhejiang University of Technology, China. After that, she entered Prof. Zhang’s group of College of Pharmaceutical Science, Zhejiang University of Technology, China, working with small molecules to regulate disease-related gene to explore gene-targeted drugs under the direction of Prof W. Zhang.

Dr. Yan-Ling Wu is a professor in Molecular Immunology and now heads the Cellular and Molecular Immunology Research Group. She received Master and Doctoral degrees in Applied Life Science in 2003 and in Medicine Science in 2006, respectively, from Tohoku University, Japan. After that, she entered to Professor Minato’s group of School of Medicine, Kyoto University, Japan, as a senior researcher working in the field of molecular immunology. Her current researches focus on understanding the molecular mechanisms of gene regulation related to diseases by immune inhibitory receptors. Dr. Wu have given oral presentations in international conferences and published related papers.

Yoshimasa Tanaka received his Ph. D in Hokkaido University Graduate School of Agriculture with a specialization in Enzymology and Biochemistry. After graduation, he continued his research in the field of Immunobiology. Since 2008, he is an associate professor and works in the Center for Innovation in Immunoregulative Immunology and Therapeutics that belongs to the Kyoto University Graduate School of Medicine.

Dr. Wen Zhang is a full professor with 25 years of research and teaching experience in Bioorganic Chemistry and Chemical Biology. Dr. Zhang earned his doctorate degree in Bioorganic Chemistry from East China University of Science and Technology, China. Then, he entered Professor Ohrui’s Lab of Tohoku University, Japan, working in the field of molecular recognition as a JSPS postdoctoral fellow. After that, he moved to Kyoto University, Japan, to join Professor Sugiyama’s Chemical Biology group as a COE and JST research fellow working on biology and chemistry of polyamide-nucleic acids interaction. Now, Dr. Zhang has a special interest in elucidating the gene regulation mechanisms with small organic molecules and the development of gene-targeted drug. His group formed in 2008 and established an extremely fruitful collaboration with Prof. Sugiyama’s Group in order to better pursue aspects of gene-targeted drug research. To date, Dr. Zhang has published better papers as the first/corresponding author in excellent Journals including JACS, JASN, ChemBioChem, Chem & Biol, ChemMedChem, Int J Biol Sci, etc.